Odyssey Therapeutics, an autoimmune disease-focused biotech, surged 11.1% in its Nasdaq debut to a $899.9 million valuation. The company raised $279 million in its IPO, surpassing its target, a result that points to renewed investor appetite for biotech listings. Founder Dr. Gary D. Glick’s track record adds extra confidence to the story.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
